Retension Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases, today announced the successful closing of its $15 million Series B financing to advance the clinical development of RTN-001 for patients with uncontrolled and resistant hypertension.

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for the treatment of hypertension and other serious cardiovascular conditions. The company's lead clinical candidate, RTN-001, focuses on the treatment of patients with uncontrolled and resistant hypertension that have difficulty regulating blood pressure despite being on two to four other antihypertensive medications.